Evaxion Biotech announced initial results from the EVX-01 Phase 2 clinical trial, confirming previous Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023. Key highlights of the initial Phase 2 results for the first five metastatic melanoma patients treated with EVX-01 include: Phase 2 data confirm the favorable safety profile of EVX-01 observed in the Phase 1 trial; Promising immunological and clinical outcomes align with the Phase 1 outcomes; Upon EVX-01 treatment, a pronounced and ongoing tumor reduction was observed in a patient with progressive disease; Phase 2 data confirms Evaxion’s AI-Immunology platform’s ability to identify therapeutically relevant cancer vaccine targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVAX:
- Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
- New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
- Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Evaxion receives Nasdaq notification regarding minimum bid price deficiency
- Evaxion partners with Afrigen Biologics to develop mRNA vaccine for gonorrhea